Request Demo
Last update 16 May 2025
Autologous lymphocytes(NCI)
Last update 16 May 2025
Overview
Basic Info
Drug Type Immune cell therapy |
Synonyms- |
Target- |
Action- |
Mechanism Cell replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
46
Clinical Trials associated with Autologous lymphocytes(NCI)ISRCTN14999554
A single-centre, experimental medicine study investigating the route of delivery and potential efficacy of autologous tolerogenic dendritic cell (tolDC) therapy for rheumatoid arthritis
KCT0005812
Double-arm, Open, Parallel Assignment, Sponsor-Initiated Trial to Evaluate the Safety and Efficacy of Pertuzumab Plus Trastuzumab Plus Docetaxel Combination with MYJ1633 (Autologous Blood-Derived Lymphocytes) in Recurrent Nonresectable or Metastatic HER-2 Positive Breast Cancer Patients
ChiCTR2100042677
Efficacy and mechanism of autologous lymphocytes in the treatment of chronic urticaria
100 Clinical Results associated with Autologous lymphocytes(NCI)
Login to view more data
100 Translational Medicine associated with Autologous lymphocytes(NCI)
Login to view more data
100 Patents (Medical) associated with Autologous lymphocytes(NCI)
Login to view more data
100 Deals associated with Autologous lymphocytes(NCI)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Melanoma recurrent | Phase 2 | United States | 01 Jul 2009 | |
| Metastatic melanoma | Phase 2 | United States | 01 Jul 2009 | |
| Anaplastic Thyroid Carcinoma | Phase 2 | United States | 31 Aug 2007 | |
| Metastatic breast cancer | Phase 2 | United States | 01 Aug 2007 | |
| Infectious Diseases | Phase 2 | United States | 30 Jun 2007 | |
| B-Cell Lymphoma | Phase 2 | United States | 21 Mar 2007 | |
| Chronic lymphocytic leukaemia refractory | Phase 2 | United States | 01 Sep 1999 | |
| Chronic lymphocytic leukaemia refractory | Phase 2 | Germany | 01 Sep 1999 | |
| Non-Hodgkin's lymphoma refractory | Phase 2 | United States | 01 Sep 1999 | |
| Non-Hodgkin's lymphoma refractory | Phase 2 | Germany | 01 Sep 1999 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 7 | peripheral blood stem cell transplantation (PBSCT)+therapeutic autologous lymphocytes+etoposide+Cyclophosphamide+Carboplatin+Ifosfamide+Thiotepa | sjsxiijkrx(smgviocspl) = dnegviovdv qrvxeskams (xjbazzciev, tfppogeobb - mpbgeutsmy) View more | - | 30 Mar 2015 | ||
Phase 2 | 158 | (Cohort 1 - NMA, TIL, Aldesleukin) | toqvncrmub = kfhkkivqnh rwyuzaoqsw (moaptzzdab, vclvxhbfbr - zmwrdhqukc) View more | - | 27 May 2013 | ||
(Cohort 2 - NMA, CD4+ TIL, Aldesleukin) | toqvncrmub = ykxutxtpko rwyuzaoqsw (moaptzzdab, enbpsykjzg - vxmaywlgru) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free